Prostate cancer
C101 – C144
- C101: Behavioural Urinary Management of Prostate Symptoms: a phase 2 trial for testing feasibility of a self-management intervention following prostate radiotherapy
- C102: ‘The push towards primary care’: health professionals’ views on the role of primary care in the follow up of men with prostate cancer
- C103: Do prostate cancer guidelines provide enough information to have confidence in the recommendations?
- C104: Are age-specific PSA reference ranges justified? Results from the ProtecT study
- C105: PSA testing and the impact of national recommendations in general practice: a semi-qualitative study
- C106: Estimation of mean sojourn time of prostate cancer, overdiagnosis, and reduction in late stage prostate cancer due to screening with PSA
- C107: A randomised double blind phase II study of salicylate compounds and lifestyle counselling in patients with early prostate cancer
- C108: 360˚ evaluation of a new follow-up service for men with early stage prostate cancer treated with radiotherapy
- C109: Prostate cancer treatment and survival by ethnic group in South East England
- C110: Exposure to sunlight and prostate cancer
- C111: Incidence, diversity and clinical relevance of ETV1 translocations in human prostate cancer
- C112: Identification of multiple novel prostate cancer predisposition loci
- C113: High frequency of t(4;6) translocation and 6q15 deletion in prostate cancer
- C114: Improving trial conduct through a new site monitoring and review process (SMART): experience from the ProtecT study
- C115: Diethylstilboestrol is active in docetaxel treated androgen independent prostate cancer
- C116: Efficacy of docetaxel re-treatment as second- and third-line chemotherapy in metastatic hormone refractory prostate cancer patients pre-treated with docetaxel
- C117: Source data verification in a multi-centre randomised controlled trial: the ProtecT study
- C118: Combination of finasteride with the chemopreventive agent resveratrol, decreases proliferative capacity of prostate cancer cells at physiologically achievable doses
- C119: NO-sulindac inhibits the hypoxia response of prostate cancer cells via the Akt signalling pathway
- C120: A single institution’s experience of over 200 cases of robotic-assisted radical prostatectomy
- C121: Functional wellbeing and lower-limb skeletal muscle function in prostate cancer patients on androgen deprivation therapy (ADT)
- C122: Modulation of androgen receptor activity in prostate cancer progression and therapy
- C123: Development of a stereo image guidance system to assist robotic surgery of prostate cancer using augmented reality
- C124: siRNA target selection using machine learning techniques: genes implicated in aggressive prostate cancer
- C125: Genetic susceptibility to prostate cancer due to rare mutations in genes in the DNA repair pathway
- C126: Modification by ubiquitin, sumo and intrinsic nuclear and nucleolar localisation signals targets lyric to sub-nuclear compartments
- C127: Characterisation of prostate stem-like cells from phosphatase and tensin homolog (PTEN) deficient mice
- C128: Identification and characterisation of side population (SP) cells in normal and cancer prostate cell lines
- C129: Analysis of factors influencing survival in patients with metastatic hormone-refractory prostate cancer (mHRPC) following GVAX immunotherapy for prostate cancer
- C130: Endogenous Prostate Apoptosis Response-4 (Par-4) inhibits in vitro growth and motility of prostate cancer cells
- C131: Mechanisms of androgen receptor activation in advanced prostate cancer: differential coactivator recruitment and gene expression
- C132: The effect of knockdown of ROCK II on the in vitro invasion and motility of PC3 prostate cancer cells
- C133: The role of Sox9 in prostate development and cancer
- C134: Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer with respect to the outcome of radical treatment
- C135: Integration of ERG gene mapping and gene expression profiling identifies distinct categories of human prostate cancer
- C136: Circulating Tumor Cell (CTC) counts as intermediate endpoints in Castration-Resistant Prostate Cancer (CRPC): a single centre experience
- C137: Prostate tumours with PTEN loss detected by fluorescent in situ hybridisation (FISH) have a worse clinical outcome and are enriched for ETS gene alterations
- C138: Identification of candidate biomarkers associated with prostate cancer progression using a proteomic 8-plex iTRAQ approach
- C139: Psychological distress and prostate specific antigen levels in men with and without prostate cancer
- C140: Rectal contouring variability in patients treated with radical radiotherapy for prostate carcinoma and its impact on rectum dose-volume histograms: pilot study
- C141: Preclinical development strategy for regulatory approval of a Phase I Trial of 99mTc Demobesin-4 (99mTc DB4) for prostate cancer imaging
- C142: A prospective study of clinically significant fatigue (CSF) after prostate brachytherapy (PB)
- C143: Salvage radiotherapy for biochemical relapse of prostate cancer after prostatectomy
- C144: Monitoring prostate cancer progression with Diffusion Weighted Imaging: variability of perfusion and diffusion components of the Apparent Diffusion Coefficient
